A. Zapatero

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
A Zapatero, A. Zapatero, Almudena Zapatero
Publication record
162 papers · 2,363 citations · H-index 25

PAPERS

Impact of image-guided radiation therapy with intraprostatic seeds on long-term toxicity in prostate cancer patients undergoing risk-adapted intensification therapy.
20260 citationsauthor #1
Risk-adapted intensification therapy in high-risk prostate cancer: how relevant is the role of radiation dose
20251 citationsauthor #1
Optimal Duration of Androgen Deprivation Therapy With Definitive Radiotherapy for Localized Prostate Cancer: A Meta-Analysis.
20252 citationsauthor #4
Long-Term Safety Data from a Real-World Cohort of 1010 Localized Prostate Cancer Men Treated with Risk-Adapted Intensification Radiotherapy Protocols
20240 citationsauthor #1
Real World Long-Term Outcome and Patterns of Failure in a Cohort of 1010 Localized Prostate Cancer Treated with Risk-Adapted Intensification Radiotherapy
20240 citationsauthor #1
Functional imaging guided stereotactic ablative body radiotherapy (SABR) with focal dose escalation and bladder trigone sparing for intermediate and high-risk prostate cancer: study protocol for phase II safo trial
20241 citationsauthor #1
Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials
202411 citationsauthor #16
Natural History after Likely Cure vs. Recurrence vs. after ProsTate RadiOtheRapy (RAPTOR): A Pooled Analysis of More than 13000 Patients from 21 Randomized Controlled Trials
20240 citationsauthor #18
A Phase II Trial of Stereotactic Body Radiation Therapy and Androgen Deprivation for Oligometastases in Prostate Cancer (SBRT-SG 05).
202410 citationsauthor #16
Recommendations on the Treatment of Metastatic Hormone-Sensitive Prostate Cancer: Patient Selection.
20242 citationsauthor #2
Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): A Pooled Analysis of Five Randomized Trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium.
202414 citationsauthor #6
SP-0998 ESTRO-ACROP guideline on prostate bed delineation for postoperative radiotherapy in prostate cancer
20230 citationsauthor #10
Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022.
2023129 citationsauthor #116
Individual Patient Data Analysis of 17 Randomized Trials vs. Real-World Data for Men with Localized Prostate Cancer Receiving Radiotherapy.
20230 citationsauthor #17
Prognostic impact of PSA nadir (n) ≥0.1 ng/mL within 6 months (m) after completion of radiotherapy (RT) for localized prostate cancer (PCa): An individual patient-data (IPD) analysis of randomized trials from the ICECAP collaborative.
20232 citationsauthor #17
OC-0270 Metastases-directed SRT and systemic therapy: EORTC-ESTRO OligoCare delphi consensus recommendations
20230 citationsauthor #21
Biochemical recurrence (BCR) surrogacy for clinical outcomes after radiotherapy for adenocarcinoma of the prostate (BCRSCRAP): A meta-analysis from MARCAP Consortium.
20230 citationsauthor #17
ESTRO ACROP consensus recommendation on the target volume definition for radiation therapy of macroscopic prostate cancer recurrences after radical prostatectomy
20234 citationsauthor #11
Biochemical Recurrence Surrogacy for Clinical Outcomes After Radiotherapy for Adenocarcinoma of the Prostate
202322 citationsauthor #21
ESTRO ACROP guideline on prostate bed delineation for postoperative radiotherapy in prostate cancer
202323 citationsauthor #10
Node Oligorecurrence in Prostate Cancer: A Challenge
20234 citationsauthor #1
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium.
2023127 citationsauthor #21
PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 Trial.
202323 citationsauthor #15
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis.
2022126 citationsauthor #10
Magnetic Resonance Imaging-guided Focal Boost to Intraprostatic Lesions Using External Beam Radiotherapy for Localized Prostate Cancer: A Systematic Review and Meta-analysis.
202214 citationsauthor #8
Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021.
2022111 citationsauthor #84
Reply to Leonard P. Bokhorst and Berdine L. Heesterman's Words of Wisdom re: High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localised Prostate Cancer (DART 01/05): 10-Year Results of a Phase 3 Randomised, Controlled Trial. Eur Urol. 2022;82:441.
20220 citationsauthor #1
Advances in Transversal Topics Applicable to the Care of Bladder Cancer Patients in the Real-World Setting
20222 citationsauthor #8
Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer
202240 citationsauthor #4
PEACE V – Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute toxicity of a randomized phase II trial
20221 citationsauthor #15
Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
2022102 citationsauthor #116
High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial.
202231 citationsauthor #1
Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials
202234 citationsauthor #22
Optimal Duration of Androgen Deprivation Therapy (ADT) with Definitive Radiotherapy for Prostate Cancer: An Individual Patient Data (IPD) Meta-Analysis from the International MARCAP Consortium
20221 citationsauthor #4
Testosterone levels and testosterone kinetics: The importance of its clinical significance.
20221 citationsauthor #1
Recommendations for Radiation Therapy in Oligometastatic Prostate Cancer: an ESTRO-ACROP Delphi consensus.
202269 citationsauthor #23
High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.
202236 citationsauthor #26
OC-0608 Phase II trial of hypofractionated postoperative radiotherapy in prostate cancer: NCT02192788
20220 citationsauthor #2
124P Feasibility of multidisciplinary translational CAPRICE project: Study protocol and workflow
20220 citationsauthor #8
Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study
20221 citationsauthor #34
OC-0603 PEACE V – STORM randomized phase II trial for oligorecurrent nodal prostate cancer: acute toxicity
20220 citationsauthor #15
Corrigendum to “What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021” [Eur Urol 82(1):6–11]
20220 citationsauthor #84
Oligorecurrent nodal prostate cancer: radiotherapy quality assurance of the randomized PEACE V-STORM phase II trial.
20228 citationsauthor #23
PD-0807 MRI-Guided focal boost to intraprostatic lesion using VMAT in prostate cancer. A Phase II Trial.
20210 citationsauthor #1
Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: results from a phase iii trial.
202111 citationsauthor #1
Impact of High DosE rAdioTherapy (HEAT) in Localized Prostate Cancer: An Individual Patient Data (IPD) Meta-Analysis of 15 Randomized Trials.
20210 citationsauthor #17
OC-0508 ESTRO ACROP Guideline on Prostate Bed Delineation for Postoperative Radiotherapy in Prostate Cancer
20210 citationsauthor #10
Phase II Trial of SBRT and Androgen Deprivation for Oligometastases in Prostate Cancer.
20217 citationsauthor #16
OC-0338 Prognostic value of testosterone following androgen deprivation and high-dose radiotherapy in prostate cancer
20210 citationsauthor #1
10-Year Results of a Phase III Randomized Trial of High-Dose Radiotherapy and Risk-Adapted Androgen Deprivation in Localized Prostate Cancer.
20210 citationsauthor #1
MRI-guided focal boost to dominant intraprostatic lesion using volumetric modulated arc therapy in prostate cancer. Results of a phase II trial.
20218 citationsauthor #1
Ten-Year Results of a Phase III Randomised Trial of High-Dose Radiotherapy and Risk-Adapted Androgen Deprivation in Localised Prostate Cancer
20211 citationsauthor #1
Health-related quality of life in men with localized prostate cancer treated with radiotherapy: validation of an abbreviated version of the Expanded Prostate Cancer Index Composite for Clinical Practice in Spain
20212 citationsauthor #1
Radiotherapy impact on health-related quality of life in localized prostate cancer: results of an observational, non-interventional, multicenter study in Spain
20210 citationsauthor #1
VMAT Focal Boost to MRI-Defined Intraprostatic Lesion in Localized Prostate Cancer: Results of a Phase II Trial.
20210 citationsauthor #1
Prognostic and Predictive Performance of Routine Clinicopathologic Variables in 10,535 Men Enrolled on Randomized Phase III Trials in Localized Prostate Cancer.
20212 citationsauthor #4
Dosimetric impact of rectum and bladder anatomy and intrafractional prostate motion on hypofractionated prostate radiation therapy
20218 citationsauthor #2
PO-1712 Oligorecurrent nodal prostate cancer: radiotherapy QA of the randomized PEACE V-STORM phase II trial
20210 citationsauthor #14
Individual Patient Data Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium: Impact of Androgen Deprivation Therapy Use and Duration With Definitive Radiotherapy for Localized Prostate Cancer.
20212 citationsauthor #13
The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases.
202025 citationsauthor #20
Prognostic Value of Testosterone Levels Following Androgen Deprivation And High Dose Radiotherapy In Localized Prostate Cancer: Results From Dart 01/05 Phase III Trial
20200 citationsauthor #1
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019.
2020344 citationsauthor #71
Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study
20201 citationsauthor #1
PO-1640: Dosimetric impact of rectum and bladder anatomy during hypofractionated prostate radiation therapy
20200 citationsauthor #6
PO-1609: Dosimetric effect of intrafraction motion on hypofractionated prostate radiation therapy plans
20200 citationsauthor #5
Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: a prospective phase II study
202032 citationsauthor #1
Positive prostate biopsy following radiotherapy can predict metastasis-free survival in localized prostate cancer.
20205 citationsauthor #1
author reply.
20190 citationsauthor #2
Phase II Trial of SBRT and Hormone Therapy for Oligometastases in Prostate Cancer
20193 citationsauthor #17
Salvage brachytherapy for locally-recurrent prostate cancer after radiation therapy: A comparison of efficacy and toxicity outcomes with high-dose rate and low-dose rate brachytherapy.
201927 citationsauthor #11
Long-term Outcomes and Patterns of Failure Following Trimodality Treatment With Bladder Preservation for Invasive Bladder Cancer.
201921 citationsauthor #2
Survival after biochemical failure in prostate cancer treated with radiotherapy: Spanish Registry of Prostate Cancer (RECAP) database outcomes
20197 citationsauthor #3
Positive Prostate Biopsy Following Radiation Therapy Can Predict Metastasis-Free Survival In Localized Prostate Cancer
20182 citationsauthor #1
Salvage Brachytherapy in Prostate Cancer after Radiation Failure: HDR vs LDR
20180 citationsauthor #11
Impact of rectum and bladder anatomy in intrafractional prostate motion during hypofractionated radiation therapy
201814 citationsauthor #2
"PRIME Study": Searching for immune biomarkers in advanced castration resistant prostate cancer (CRPC) patients treated with standard therapy.
20180 citationsauthor #2
EP-2018: Components of prostate displacement during hypofractionated radiotherapy treatment
20180 citationsauthor #3
Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology
20189 citationsauthor #5
Impact of Rectum and Bladder Anatomy in Intrafractional Prostate Motion During Hypofractionated Radiation Therapy
20180 citationsauthor #2
Survival after Biochemical Failure in Prostate Cancer Treated with Radiation Therapy
20180 citationsauthor #3
PO-0832: Long-term outcomes following organ preservation treatment for muscle invasive bladder cancer
20180 citationsauthor #2
Multicomponent Assessment of the Geometrical Uncertainty and Consequent Margins in Prostate Cancer Radiotherapy Treatment Using Fiducial Markers
20184 citationsauthor #3
Hypofractionated Radiation Therapy Using Fiducial Markers: Assessment of Residual Error and Variation of Prostate Volume during Treatment
20180 citationsauthor #3
Procedures and recommended times in the care process of the patient with pancreatic cancer: PAN-TIME consensus between scientific societies
20175 citationsauthor #12
Erratum to: Procedures and recommended times in the care process of the patient with pancreatic cancer: PAN-TIME consensus between scientific societies
20172 citationsauthor #12
Monitoring of Circulating Tumor Cells in Patients With High-Risk Nonmetastatic Prostate Cancer Treated With Radiation Therapy and Hormones: Preliminary Data of an Observational Prospective Phase 2 Study
20170 citationsauthor #1
Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer
201728 citationsauthor #1
Corrigendum to "Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance". [Rep. Pract. Oncol. Radiother. 20 (2015) 259-272].
20162 citationsauthor #3
Late Radiation and Cardiovascular Adverse Effects After Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Results From the DART 01/05 Randomized Phase 3 Trial.
201632 citationsauthor #1
Improved Late Rectal and Urinary Toxicity With High-Dose Intensity Modulated Radiation Therapy Using Intraprostate Fiducial Markers for Localized Prostate Cancer
20161 citationsauthor #1
Androgen Deprivation and High-Dose Radiation Therapy in Prostate Cancer: Report on Late Toxicity from DART 01/05 Randomized Phase III Trial
20161 citationsauthor #1
Management of prostate cancer patients following radiation therapy after radical surgery referred from urology to radiation oncology departments in Spain
20161 citationsauthor #2
Correction to Lancet Oncol 2015; 16: 324. High-dose radiotherapy with shortterm or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
20153 citationsauthor #1
Uroncor consensus statement: Management of biochemical recurrence after radical radiotherapy for prostate cancer: From biochemical failure to castration resistance.
201516 citationsauthor #3
Reporting of results in DART01/05 GICOR - Author's reply.
20151 citationsauthor #1
Androgen deprivation and radiotherapy in patients with prostate cancer and cardiovascular risk factors: clinical controversies
20153 citationsauthor #1
High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 trial.
2015284 citationsauthor #1
Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapy
20151 citationsauthor #4
HIF1A expression in localized prostate cancer treated with dose escalation radiation therapy
201511 citationsauthor #1
Long-term versus short-term androgen deprivation combined with high-dose radiotherapy for intermediate and high-risk prostate cancer: A randomized controlled trial (DART01/05)
20142 citationsauthor #1

TIMELINE

1994 0 citations

1995 0 citations

1996 14 citations

1997 0 citations

2000 33 citations

2002 5 citations

2003 83 citations

2005 70 citations

2006 13 citations

2007 0 citations

2008 15 citations

2009 46 citations

2010 63 citations

2011 36 citations

2012 87 citations

2013 7 citations

2014 20 citations

2015 319 citations

2016 37 citations

2017 35 citations

2018 29 citations

2019 58 citations

2020 407 citations

2021 41 citations

2022 577 citations

2023 334 citations

2024 38 citations

2025 3 citations

2026 0 citations

A. Zapatero

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT